← Back to list
Oakmark FundsQuarterly30 Jun 2025Source: oakmark.com

Oakmark Fund: Second Calendar Quarter 2025

Oakmark is the mutual fund family launched in 1991 by Harris Associates, the Chicago deep-value firm founded in 1976 (about $105bn AUM). Bill Nygren runs the flagship Oakmark Fund and David Herro the Oakmark International Fund, buying businesses at large discounts to intrinsic value and holding them like owners — publishing quarterly fund commentaries, market commentaries and insight articles.

Bill Nygren、David Herro · 1991 · 美国芝加哥Deep value / contrarian long-term

In plain words

This report explains how Oakmark Fund navigated the tariff panic in the second quarter of 2025. They sold stocks that held up well and bought deeply discounted shares of solid companies like Nike and Amazon, boosting their margin of safety. They also used a 'put writing' strategy to buy Salesforce: they sold put options (promising to buy at a set price) and collected a premium, effectively getting a discount. The fund sees Global Payments as misunderstood—the market reacted negatively to its acquisition, but Oakmark believes the company can return nearly a third of its market value to shareholders over three years. The takeaway for regular investors: don't panic during selloffs; look for quality stocks that have fallen too far, and consider options strategies to lower your cost.

AI SummaryAI-generated · may contain errors · verify against the original

Oakmark Fund's Q2 2025 report shows that the fund (Investor Share Class) underperformed the S&P 500 Index during the quarter but has outperformed since inception. The core view is that, leveraging the market panic triggered by tariffs, the fund actively adjusted its portfolio, reducing holdings in s

~4 min full read · 5 sections
Deep Analysis

Theme and Background

This chapter is the opening overview of Oakmark Fund’s second-quarter 2025 report, focusing on how the fund actively adjusted its portfolio amid market volatility triggered by tariff fears. The report notes that the fund underperformed the S&P 500 Index for the quarter but has outperformed cumulatively since inception.

Core Views

The author’s core investment thesis is to exploit market dislocations caused by tariff fears through active opportunistic rebalancing—reducing positions in stocks with relatively resilient prices and increasing holdings in assets whose declines far exceed intrinsic value, thereby enhancing the margin of safety and potential returns. The author argues that such opportunistic portfolio management can enhance client returns.

Counterintuitive judgment: Despite the market’s negative reaction to Global Payments’ acquisition of Worldpay, the author believes investors underestimate the long-term strategic and financial value of the deal, and that the company can return nearly one-third of its market capitalization to shareholders over the next three years.

Key Arguments and Data

  • Rebalancing Logic: At the start of the second quarter, tariff fears created opportunities. The fund reduced holdings in companies whose stock prices remained relatively firm during the market turmoil and increased or initiated positions in assets whose price declines far exceeded intrinsic value.
  • Salesforce Position-Building Strategy: Since exiting in December, the stock has fallen over 30%, but fundamentals met expectations. The fund built the position using a put writing strategy, believing the options were overvalued (implied volatility suggested Salesforce was one of the most volatile large companies, which the author considers completely inconsistent with its business value assessment), thereby reducing the cost of entry.
  • Nike Decline: Since its 2021 peak, the stock has fallen to approximately one-third of its prior high (i.e., a decline of about two-thirds).
  • Global Payments Capital Return: The author believes the company can return close to one-third of its current market capitalization to shareholders over the next three years, and that capital returns could grow further as the full benefits of the Worldpay transaction are realized.

Companies/Assets Involved

Company Role Key Data Bullish/Bearish
Citigroup Largest contributor for the quarter Q1 results beat expectations, full-year guidance reaffirmed, buybacks accelerated; benefited from expectations of bank deregulation Bullish
Global Payments Largest detractor for the quarter Negative reaction to the acquisition of Worldpay and divestiture of Issuer Solutions; author believes nearly one-third of market cap can be returned Bullish (contrarian to market consensus)
Salesforce New position Stock down over 30% since exit in December, fundamentals in line; position built via put writing Bullish
Amazon New position World’s largest online retailer and cloud service provider; stock fell on tariff and macro concerns, author bought at a discount to intrinsic value Bullish
Nike Cl B New position Down to about one-third of 2021 peak; new CEO plans to improve wholesale relationships and product innovation Bullish
Zimmer Biomet New position Pure-play orthopedics company; new management completed multi-year reforms, but market has not yet priced this in, valuation below peers and the market Bullish
BorgWarner Liquidated No specific reason provided Bearish (liquidated)

Investment Insights

  • Contrarian Position-Building Amid Panic: Tariff-induced market declines offer discounted entry opportunities into high-quality companies (e.g., Amazon, Nike). Investors should focus on assets whose price declines far exceed fundamental deterioration.
  • Options Strategies to Reduce Risk: For high-volatility but fundamentally sound stocks (e.g., Salesforce), building positions via put writing can lower entry costs by capturing option premiums.
  • Focus on Misunderstood Transactions: Global Payments’ acquisition faced a negative market reaction, but the author believes its long-term strategic value is underestimated and its capital return commitment is strong (nearly one-third of market cap). Such opportunities may offer excess returns.
  • Medical Device Sector Valuation Gap: Zimmer Biomet’s valuation is below peers and the market, and the new management’s reforms have yet to be recognized. Orthopedics benefits long-term from aging demographics and the adoption of robotic surgery.